Bioavailability of dexmedetomidine after extravascular doses in healthy subjects

British Journal of Clinical Pharmacology

Volumn 56, Issue 6, 2003, Pages 691-693

  Anttila, Markku ^a   Penttilä, Jani ^b,c   Helminen, Antti ^b,d   Vuorilehto, Lauri ^a   Scheinin, Harry ^b,e  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Bioavailability; Dexmedetomidine; Pharmacokinetics

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DEXMEDETOMIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MOUTH MUCOSA; NORMAL HUMAN; PRIORITY JOURNAL;

ADRENERGIC ALPHA-AGONISTS; ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DEXMEDETOMIDINE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; MALE;

EID: 0344943299     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01944.x     Document Type: Article

References (12)

1. Aantaa R, Kallio A, Virtanen R. Dexmedetomidine, a novel alpha 2-adrenergic agonist. A review of its pharmacodynamic characteristics. Drugs Future 1993; 18: 49-56.
2. Kuusela E, Raekallio M, Anttila M, Falck I, Molsa S, Vainio O. Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs. J Vet Pharmacol Ther 2000; 23: 15-20.
3. Ben-Abraham R, Ogorek D, Weinbroum AA. Dexmedetomidine: a promising agent for anesthesia and perioperative care. Isr Med Assoc J 2000; 2: 793-796.
4. Scheinin H, Jaakola ML, Sjövall S et al. Intramuscular dexmedetomidine as premedication for general anesthesia. A comparative multicenter study. Anesthesiology 1993; 78: 1065-1075.
5. Angelini G, Ketzler JT, Coursin DB. Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit. Crit Care Clin 2001; 17: 863-880.
6. De Wolf AM, Fragen RJ, Avram MJ, Fitzgerald PC, Rahimi-Danesh F. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg 2001; 93: 1205-1209.
7. Dutta S, Lal R, Karol MD, Cohen T, Ebert T. Influence of cardiac output on dexmedetomidine pharmacokinetics. J Pharm Sci 2000; 89: 519-527.
8. Scheinin H, Karhuvaara S, Olkkola KT et al. Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. Clin Pharmacol Ther 1992; 52: 537-546.
9. Dyck JB, Maze M, Haack C, Vuorilehto L, Shafer SL. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology 1993; 78: 813-820.
10. Kivistö KT, Kallio A, Neuvonen PJ. Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine. Eur J Clin Pharmacol 1994; 46: 345-349.
11. Shah VP, Midha KK, Dighe S et al. Analytical methods validation: Unavailability, bioequivalence, and pharmacokinetic studies. Conference report. Pharm Res 1992; 9: 588-592.
12. Vuorilehto L, Salonen JS, Anttila M. Picogram level determination of medetomidine in dog serum by capillary gas chromatography with negative ion chemical ionization mass spectrometry. J Chromatogr 1989; 497: 282-287.